Derivation and validation of a simple clinical risk-model in heart failure based on 6 minute walk test performance and NT-proBNP status - Do we need specificity for sex and beta-blockers?

International Journal of Cardiology

Volumn 147, Issue 1, 2011, Pages 74-78

  Frankenstein, L ^a   Goode, K ^c   Ingle, L ^b   Remppis, A ^a   Schellberg, D ^a   Nelles, M ^a   Katus, H A ^a   Clark, A L ^c   Cleland, J G F ^c   Zugck, C ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b LEEDS METROPOLITAN UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Beta blockers; Chronic heart failure; Risk prediction; Sex

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

6 MINUTE WALK TEST; ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SYSTOLIC DYSFUNCTION; TASK PERFORMANCE; VALIDATION PROCESS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; PSYCHOMOTOR PERFORMANCE; RISK FACTORS; SEX CHARACTERISTICS; TIME FACTORS; WALKING;

EID: 79951722599     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.08.005     Document Type: Article

References (40)

1. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7. (Pubitemid 27255495)
2. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113:1424-33. (Pubitemid 43739439)
3. Jessup M, Pina IL. Is it important to examine gender differences in the epidemiology and outcome of severe heart failure? J Thorac Cardiovasc Surg 2004;127:1247-52.
4. Zugck C, Haunstetter A, Kruger C, et al. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 2002;39:1615-22. (Pubitemid 34494284)
5. Ingle L, Shelton RJ, Rigby AS, Nabb S, Clark AL, Cleland JG. The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure. Eur Heart J 2005;26:1742-51. (Pubitemid 41219847)
6. Demers C, McKelvie RS, Negassa A, Yusuf S. RESOLVD Pilot Study Investigators. Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. Am Heart J 2001;142:698-703. (Pubitemid 32900498)
7. Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA 1993;270:1702-7. (Pubitemid 23295315)
8. Ingle L, Rigby AS, Carroll S, et al. Prognostic value of the 6 min walk test and selfperceived symptom severity in older patients with chronic heart failure. Eur Heart J 2007;28:560-8. (Pubitemid 47355515)
9. Chetta A, Zanini A, Pisi G, et al. Reference values for the 6-min walk test in healthy subjects 20-50 years old. Respir Med 2006;100:1573-8. (Pubitemid 44089362)
10. Gibbons WJ, Fruchter N, Sloan S, Levy RD. Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. J Cardiopulm Rehabil 2001;21:87-93. (Pubitemid 32275133)
11. Genth-Zotz S, Zotz RJ, Sigmund M, et al. MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. Eur J Heart Fail 2000;2:175-81. (Pubitemid 30407558)
12. Sanderson JE, Chan SK, Yip G, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999;34:1522-8. (Pubitemid 29528667)
13. KukinML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-51. (Pubitemid 29237451)
14. Abdulla J, Kober L, Christensen E, Torp-Pedersen C. Effect of beta-blocker therapy on functional status in patients with heart failure-a meta-analysis. Eur J Heart Fail 2006;8:522-31. (Pubitemid 44205499)
15. Curtis JP, Rathore SS, Wang Y, Krumholz HM. The association of 6-minute walk performance and outcomes in stable outpatients with heart failure. J Card Fail 2004;10:9-14. (Pubitemid 38880886)
16. Roul G, Germain P, Bareiss P. Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure? AmHeart J 1998;136:449-57.
17. Zugck C, Kruger C,Durr S, et al. Is the 6-minutewalk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy? Eur Heart J 2000;21:540-9.
18. Rostagno C, Olivo G, Comeglio M, et al. Prognostic value of 6-minute walk corridor test in patients with mild to moderate heart failure: comparison with other methods of functional evaluation. Eur J Heart Fail 2003;5:247-52. (Pubitemid 37011852)
19. Ingle L, Rigby AS, Nabb S, Jones PK, Clark AL, Cleland JG. Clinical determinants of poor six-minute walk test performance in patients with left ventricular systolic dysfunction and no major structural heart disease. Eur J Heart Fail 2006;8:321-5. (Pubitemid 43674495)
20. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004;164:1978-84. (Pubitemid 39390553)
21. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005;330:625.
22. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal terminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30. (Pubitemid 30172933)
23. Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M, Giannessi D. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 2002;40:371-7. (Pubitemid 34546234)
24. Luchner A, Burnett Jr JC, Jougasaki M, Hense HW, Riegger GA, Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 1998;32:1839-44. (Pubitemid 29010443)
25. Frankenstein L, Nelles M, Slavutsky M, et al. Beta-blockers influence the shortterm and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents. J Heart Lung Transplant 2007;26:1033-9. (Pubitemid 47500149)
26. RemmeWJ, Swedberg K. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail 2002;4:11-22.
27. Frankenstein L, Remppis A, Graham J, et al. Gender and age related predictive value of walk test in heart failure: Do anthropometrics matter in clinical practice? Int J Cardiol 2008;127:331-6.
28. Yeo KT,WuAH, Apple FS, et al.Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338:105-7.
29. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
30. Harrell Jr FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543-6. (Pubitemid 12155954)
31. Gonen M. Analyzing Receiver Operating Characteristic Curves Using SAS. Cary, NC: SAS Press; 2007.
32. Efron B. Bootstrap Methods: Another Look at the Jackknife. Ann Statist 1979;7:1-26.
33. Rostagno C, Galanti G, Romano M, Chiostri G, Gensini GF. Prognostic value of 6-minute walk corridor testing in women with mild to moderate heart failure. Ital Heart J 2002;3:109-13. (Pubitemid 34591553)
34. Christ M, Laule-Kilian K, Hochholzer W, et al. Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: insights from the B-type natriuretic peptide for acute shortness of breath evaluation study. J Am Coll Cardiol 2006;48:1808-12. (Pubitemid 44648609)
35. Komajda M, Follath F, Swedberg K. et al.; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology.The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24:464-74.
36. Butler J, Khadim G, Paul KM, et al. Selection of patients for heart transplantation in the current era of heart failure therapy. J Am Coll Cardiol 2004;43:787-93. (Pubitemid 38296477)
37. May HT, Horne BD, Levy WC, et al. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. Am J Cardiol 2007;100:697-700. (Pubitemid 47223146)
38. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-41. (Pubitemid 33116567)
39. Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant 2004;23:1414-22. (Pubitemid 40018165)
40. Coats AJ. Ethical authorship and publishing. Int J Cardiol 2009;131:149-50.